Flow diagram. Randomization and follow-up of the TIKI trial patients. Two hundred six patients were registered at the Web site. Four patients declined to participate, 1 patient appeared to have chronic ITP, and 1 patient appeared to have Evans’ syndrome. Of 200 eligible patients, 100 patients were randomly assigned to receive IVIg and 100 to observation. One patient did not receive IVIg because of quick spontaneous recovery of platelet counts, and 3 patients in the observation group did receive IVIg within 72 hours after inclusion because of grade 4 mucosal bleeding. No patients were lost to follow-up before they had recovered.